XXXiaobing Xi

Xiaobing Xi

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Xiaobing Xi has a total of 88 co-authors. Here are the top co-authors by number of shared publications:

  • Wei Yan

    Department of Orthopaedics , Ruijin Hospital , Shanghai Jiao Tong University School of Medicine , Shanghai 200025 , China , shsmu.edu.cn

    9 shared publications
  • Bo Kong

    Department of Orthopaedics, Shanghai Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai 200025, China

    6 shared publications
  • Changgui Wu

    Department of Orthopedics, Shanghai Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China

    6 shared publications
  • Ping Jiang

    Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China

    6 shared publications
  • Wei Yan

    Ruijin Hospital affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai, China

    6 shared publications
  • Yichen Zhao

    Department of Orthopaedics, Shanghai Key Laboratory for Prevention and Treatment of Bone and Joint Diseases, Shanghai Institute of Traumatology and Orthopaedics, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China

    6 shared publications

Latest Publications

  • Open Access

    Integrated machine learning and clinical validation identify COL21A1 as a potential biomarker for sarcopenia

    by Zhi Wang, Yidong Zhu, Ping Jiang, Yajuan Guo, Mingcong Wang, Wei Yan, Juhua Zhang, Xiaobing Xi

  • Open Access

    Acetylshikonin alleviates gouty arthritis by increasing sirtuin1 expression and promoting lymphatic drainage

    by Changgui Wu, Jun Yan, Shaohua Chen, Xiaoying Chu, Xiaobing Xi

    Gouty arthritis (GA) is a common and painful inflammatory joint disease. Acetylshikonin (Askn), a major bioactive compound extracted from the traditional C

  • Open Access

    Multi-omics data reveal causal associations of cellular senescence-related genes in rheumatoid arthritis: A summary-data-based Mendelian randomization and co-localization analysis

    by Ping Jiang, Youji Jia, Juhua Zhang, Zhi Wang, Honghong Ma, Yajuan Guo, Mingcong Wang, Wei Yan, Xiaobing Xi

    Rheumatoid arthritis (RA) is a complex autoimmune disease. Recently, cell senescence has been identified as a key factor in its pathogenesis. This study integrated multi-omics summary data and applied Mendelian randomization (MR) and co-localization analysis to systematically evaluate the causal relationships between cell senescence-related genes and RA. We collected summary data on blood methylation quantitative trait loci (mQTL), expression quantitative trait loci, and protein quantitative trait loci. The FinnGen database was the primary discovery dataset, validated by the UK Biobank and GWAS Catalog. We used the summary-data-based MR method to assess causal associations between the molecular traits of cell senescence-related genes and RA. Co-localization analysis was then performed to confirm shared genetic variants. After integrating multi-omics data on cell senescence-related mQTL and expression quantitative trait loci, we identified 5 key cell senescence-related genes potentially associated with RA: BCL2L1 , DNMT3B , ERRFI1 , NEK4 , and RAF1 . These genes demonstrated significant causal associations across multiple analyses. The mQTL signals based on summary-data-based MR analysis show that the genetically regulated methylation variations at the cg12873919 (odds ratio [OR] = 0.91, 95% CI [0.84–0.99]) and cg13989999 (OR = 0.90, 95% CI [0.82–1.00]) sites of the BCL2L1 gene are negatively associated with RA risk and may mediate disease risk by upregulating gene expression (OR = 0.82, 95% CI [0.76–0.88] and OR = 0.78, 95% CI [0.71–0.87]). Conversely, the mQTL effect size at the cg26432171 site of the RAF1 (OR = 1.17, 95% CI [1.02–1.33]) is positively associated with RA risk and is consistent with the upregulation of gene expression (OR = 1.83, 95% CI [1.49–2.25]), thereby enhancing RA susceptibility. Moreover, several sites in the DNMT3B gene (e.g., cg09149842) exhibited negative correlations with RA risk, suggesting that DNMT3B may play a critical role in RA pathogenesis by affecting gene expression. Methylation sites in ERRFI1 (cg13808198, cg22678073) and NEK4 (cg09524078) were also associated with RA risk, supporting their potential regulatory roles in RA. Co-localization analysis further validated the association between methylation sites and RA, particularly for BCL2L1 , RAF1 , DNMT3B , ERRFI1 , and NEK4 , where we identified shared causal signals with RA (posterior probability of H4 > 0.5). This study systematically evaluated the causal relationships between cell senescence-related genes and RA risk. These findings provide new insights into RA pathogenesis and reinforce the clinical value of these genes as potential therapeutic targets.


  • Open Access

    PLCG2 across human disease: genetic variants, signaling mechanisms, and clinical implications

    by Ping Jiang, Mingcong Wang, Chengzhe Zhang, Xiaopeng Li, Zhi Wang, Yajuan Guo, Juhua Zhang, Wei Yan, Xiaobing Xi

    Phospholipase Cγ2 (PLCG2) serves as a central signal transducer within immune and neural lineages, catalyzing the conversion of membrane phosphoinosit


  • Open Access

    Research Trends and Insights in Chronic Nonspecific Low Back Pain: Bibliometric Analysis (1996–2025)

    by Wei Yan, Lingjun Kong, Tianxiang He, Xin Zhou, Guangxin Guo, Qingguang Zhu, Xiaobing Xi, Min Fang

    Background: Chronic nonspecific low back pain (CNLBP) is a major global driver of disability, with increasing attention toward individualized, evidence‐based, and function‐oriented interventions. To delineate the global CNLBP research landscape, we conducted a bibliometric and visualization analysis covering the period from 1996 to 2025. Methods: Publications were retrieved from the Web of Science Core Collection, and VOSviewer, CiteSpace, and the R package bibliometrix were used to examine publication growth, author output, contributions by countries and institutions, journal influence, keyword co‐occurrence patterns, and citation burst signals. Results: A total of 937 peer‐reviewed articles were identified, authored by 4,336 individuals across 288 journals and 65 countries. The largest share of publications was contributed by the United States, while Australia demonstrated strong international collaboration and citation impact. Institutions such as Vrije Universiteit Amsterdam, University of Southern Denmark, and University of Sydney played leading roles in CNLBP research output. Influential authors included Peter O’Sullivan and Kieran O’Sullivan, noted for contributions to psychosocial modeling and individualized rehabilitation. Keyword co‐occurrence analysis identified four thematic clusters: (1) disease definition and epidemiology; (2) evidence‐based management and health systems; (3) neuromechanical rehabilitation strategies; and (4) psychosocial dimensions and patient‐centered outcomes. Burst keyword analysis revealed recent focus on “motor control” (2021–2024), “Tampa scale” (2023–2025), and “quality of life” (2023–2025), reflecting the shift toward precision rehabilitation and multidimensional assessment. Conclusions: A comprehensive overview of the evolving CNLBP research landscape was provided through this bibliometric analysis. Findings underscore the transition from diagnostic exploration to integrated clinical interventions, with growing emphasis on function, psychological well‐being, and personalized care pathways.

  • Open Access

    Efficacy of Tuina in patients with knee osteoarthritis: study protocol for a randomised controlled trial

    by Jinlin Zhang, Bin Xue, Yan Wei, Ming Shi, Yi Luo, Weijia Chen, Qiang Wang, Xiaobing Xi, Zhijun Hu

    Background: Tuina demonstrates clinical therapeutic efficacy in the treatment of knee osteoarthritis (KOA). However, due to the paucity of high-quality and credible evidence-based medical evidence, there is no unified consensus on the treatment of KOA with Tuina in the current medical guidelines. Therefore, we will conduct a two-arm parallel group design and a randomised controlled trial to evaluate the efficacy of Tuina for treating KOA and the effect of Tuina on various muscles of the knee joint. Methods and analysis: A total of 84 participants from Ruijin Hospital Affiliated to Shanghai Jiao Tong University School of Medicine will be recruited. The participants will be randomly assigned to the Tuina group or the Infrared group in a 1:1 ratio. Participants in the Tuina group will receive manual therapy and infrared therapy, while the infrared group will receive infrared therapy exclusively. Both groups will undergo treatment twice per week during the 4-week treatment period and will be followed up at months 3 and 6 post-treatment period. All participants will receive healthcare education (encompassing knee joint exercise and protection) throughout the study duration. The primary outcome measure is the Lysholm score, which assesses the overall function of the knee joint. Secondary outcomes comprise Visual Analogue Scale, muscle tone and pressure pain threshold. All outcomes will be assessed and analysed by researchers blinded to the treatment allocation. Statistical analyses will adhere to the intention-to-treat principle. Ethics and dissemination: This trial protocol has been approved by the Ethics Committee of Ruijin Hospital (project number 2024-38). Written informed consent from study participants will be obtained prior to enrolment. The findings will be disseminated through peer-reviewed journals. Trial registration number: ITMCTR2024000469.


  • Open Access

    The Role of WNT5A-mediated proteomic and phosphoproteomic regulatory networks in rheumatoid arthritis

    by Ping Jiang, Daxi Ma, Youji Jia, Honghong Ma, Yajuan Guo, Juhua Zhang, Wei Yan, Xiaobing Xi

  • Madecassoside alleviates Clostridioides difficile infection by targeting ASC to inhibit inflammasome activation

    by Wei Chen, Yichen Zhao, Liang Hu, Danfeng Dong, Yu Zeng, Tongxuan Su, Yining Shen, Yiyue Liu, Qianli Zhao, Cen Jiang, et al.


  • Open Access

    Association between metabolic syndrome and low back pain: a two-sample Mendelian randomization study

    by Wei Yan, Lingjun Kong, Tianxiang He, Guangxin Guo, Qingguang Zhu, Xiaobing Xi, Min Fang

    This study uses two-sample MR analysis with GWAS summary statistics to evaluate the causal relationship between metabolic syndrome and low back pain. A two-sample Mendelian randomization analysis used GWAS summary statistics for low back pain from the FinnGen database and metabolic syndrome data, including waist circumference, hypertension, fasting blood glucose, HDL cholesterol, and triglyceride levels. Various methods like inverse variance weighted, MR-Egger, weighted median, and mode assessed the causal relationship, with sensitivity analyses addressing heterogeneity and pleiotropy. Our analysis found a statistically significant causal association between essential hypertension (OR 2.38, 95% CI 1.42–3.96; Padj = 0.002), metabolic syndrome (OR 1.05, 95% CI 1.01–1.10; Padj = 0.023) and waist circumference (OR 49, 95% CI 1.32–1.68; Padj < 0.001) and low back pain (OR 1.41, 95% CI 1.30–1.53, Padj < 0.001). In contrast, fasting blood glucose (FBG), HDL cholesterol, and triglycerides showed no significant associations with low back pain across all MR methods. The results of sensitivity analyses indicated that the heterogeneity and pleiotropy were unlikely to disturb the causal estimate. Our study indicates that increased essential hypertension, metabolic syndrome and waist circumference is causally associated with a higher risk of low back pain. Interventions targeting metabolic syndrome components, particularly blood pressure control and weight management, could help reduce the risk of low back pain. Further research is needed to explore the underlying biological pathways linking these metabolic factors to low back pain.